Outlook For Drug Chains: Steven Valiquette – Warburg Dillon Read Llc
STEVEN VALIQUETTE, Director, joined UBS Warburg, LLC, in 1997, and is
focused primarily on equity research of the specialty pharmaceutical
industry. He also covers the pharmacy benefit management industry, and
formerly covered the large capitalization pharmaceutical companies, the
US wholesale drug distributors and retail pharmacy chains for UBS.
Before joining UBS, Mr. Valiquette worked for three years (1995-97) in
the equity research department at Schroder & Co., where he was an
Associate Analyst in the health care services sector focused on HMOs,
nursing home chains, and physician practice management companies. Prior
to joining Schroder, he was an associate analyst in the equity research
department at Kidder, Peabody (1994), with a focus on consumer staples.
Mr. Valiquette graduated from the University of Michigan School of
Business Administration with a Bachelor's degree in Finance and
TWST: Which companies do you include in your universe of retail drug
Mr. Valiquette: The stocks I cover formally right now are CVS (CVS),